Sponsors Should Consider Representative Race, Age In Trial Design, US FDA Emphasizes
Executive Summary
A final guidance document from the agency outlines how device sponsors should approach racial, ethnic and age diversity in trial enrollment and data analysis.
You may also be interested in...
Global Medtech Guidance Tracker: September 2017
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-eight new guidance documents were posted to the tracker.
Tips For Recruiting, Reporting Trial Subpopulations In FDA Draft Guidance
FDA instructs device manufacturers and agency staff on its expectations for designing and analyzing trials to reflect outcomes for patient subpopulations, and also provides recruitment tips in a June 20 draft guidance.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.